" Ozempic face " is a common term used to describe the loss of facial fullness often seen after rapid weight loss with GLP1 receptor agonists ( semaglutide , tirzepatide , dulaglutide , etc.)
[2] Regular follow-up with healthcare providers ensures appropriate monitoring of glycemic control, weight changes, and potential adverse effects
It activates three separate receptor systems simultaneously: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors
Diabetes can cause damage to the nerves that control the salivary glands, leading to reduced saliva production and dry mouth symptoms
doi: 10.3803/EnM.2014.29.4.536 70 KrnerMStckliMWaserBReubiJC
GLP-1 Analogue Induced AKI